Impaired angiogenesis and peripheral muscle microcirculation loss contribute to exercise intolerance in pulmonary arterial hypertension

American Journal of Respiratory and Critical Care Medicine

Volumn 190, Issue 3, 2014, Pages 318-328

  Potus, François ^a   Malenfant, Simon ^a   Graydon, Colin ^a   Mainguy, Vincent ^a   Tremblay, Ève ^a   Breuils Bonnet, Sandra ^a   Ribeiro, Fernanda ^a   Porlier, Alexandra ^a   Maltais, François ^a   Bonnet, Sébastien ^a   Provencher, Steeve ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Angiogenesis; Exercise intolerance; MicroRNA; Pulmonary hypertension

Indexed keywords

MATRIGEL; MICRORNA 126; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; MICRORNA;

ADULT; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EXERCISE INTOLERANCE; EXERCISE TOLERANCE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; MALE; MICROCIRCULATION; MUSCLE BIOPSY; MUSCLE BLOOD FLOW; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUADRICEPS FEMORIS MUSCLE; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; TREADMILL TEST; UPREGULATION; ANIMAL; BIOPSY; CANADA; CASE CONTROL STUDY; DISEASE MODEL; GENETICS; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; VASCULARIZATION; WESTERN BLOTTING;

ANGIOGENESIS; EXERCISE INTOLERANCE; MICRORNA; PULMONARY HYPERTENSION;

ADULT; ANIMALS; BIOPSY; BLOTTING, WESTERN; CASE-CONTROL STUDIES; DISEASE MODELS, ANIMAL; DOWN-REGULATION; EXERCISE TOLERANCE; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MICROCIRCULATION; MICRORNAS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; QUADRICEPS MUSCLE; QUEBEC; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84905831453     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201402-0383OC     Document Type: Article

References (45)

1. Galie N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, Klepetko W, McGoon MD, McLaughlin VV, Preston IR, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013; 62:D60-D72.
2. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yäici A, Weitzenblum E, Cordier J-F, Chabot F, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122: 156-163.
3. Dimopoulos S, Tzanis G, Manetos C, Tasoulis A, Mpouchla A, Tseliou E, Vasileiadis I, Diakos N, Terrovitis J, Nanas S. Peripheral muscle microcirculatory alterations in patients with pulmonary arterial hypertension: a pilot study. Respir Care 2013;58:2134-2141.
4. Mainguy V, Maltais F, Saey D, Gagnon P, Martel S, Simon M, Provencher S. Peripheral muscle dysfunction in idiopathic pulmonary arterial hypertension. Thorax 2010;65:113-117.
5. Walley KR. Heterogeneity of oxygen delivery impairs oxygen extraction by peripheral tissues: theory. J Appl Physiol 1996;81:885-894.
6. Brodal P, Ingjer F, Hermansen L. Capillary supply of skeletal muscle fibers in untrained and endurance-trained men. Am J Physiol 1977; 232:H705-H712.
7. Tolle J, Waxman A, Systrom D. Impaired systemic oxygen extraction at maximum exercise in pulmonary hypertension. Med Sci Sports Exerc 2008;40:3-8.
8. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY, Srivastava D. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008;15:272-284.
9. Zou J, Li WQ, Li Q, Li XQ, Zhang JT, Liu GQ, Chen J, Qiu XX, Tian FJ, Wang ZZ, et al. Two functional microRNA-126s repress a novel target gene p21-activated kinase 1 to regulate vascular integrity in zebrafish. Circ Res 2011;108:201-209.journal [Published erratum appears in Circ Res 2011;108:e10.]
10. Bockmeyer CL, Maegel L, Janciauskiene S, Rische J, Lehmann U, Maus UA, Nickel N, Haverich A, Hoeper MM, Golpon HA, et al. Plexiform vasculopathy of severe pulmonary arterial hypertension and microRNA expression. J Heart Lung Transplant 2012;31: 764-772.
11. Sood N, Crawford M, Batte K, Wright V, Nana-Sinkam P. Circulating microRNA in the pathogenesis of pulmonary hypertension. Chest 2010;138:894A.
12. Potus F, Breuils-Bonnet S, Malenfant S, Provencher S, Bonnet S. Systemic microcirculation impairment is associated with exercise intolerance in pulmonary arterial hypertension. Am J Respir Crit Care Med 2014;189:A6329 [abstract].
13. Potus F, Malenfant S, Breuils-Bonnet S, Bonnet S, Provencher S. miR-126 downregulation in skeletal muscle decrease angiogenesis through VEGF pathway and contributing to exercise intolerance in pulmonary arterial hypertension. Angiogenesis 2013;16:264.
14. Potus F, Malenfant S, Breuils-Bonnet S, Margaillant G, Bonnet S, Provencher S. miR-126, angiogenesis and exercise intolerance in pulmonary arterial hypertension. Am J Respir Crit Care Med 2013; 187:A5913 [abstract].
15. Potus F, Malenfant S, Breuils-Bonnet S, Margaillant G, Bonnet S, Provencher S. miR-126 dependent decrease of skeletal muscle microcirculation contribute to exercise intolerance in pulmonary arterial hypertension. FASEB J 2013;27:A778.772 [abstract].
16. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013;62: D42-D50.
17. Andersen P, Saltin B. Maximal perfusion of skeletal muscle in man. J Physiol 1985;366:233-249.
18. Hepple RT, Hagen JL, Krause DJ. Oxidative capacity interacts with oxygen delivery to determine maximal O2 uptake in rat skeletal muscles in situ. J Physiol 2002;541:1003-1012.
19. Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009;30:394-403.
20. Duscha BD, Robbins JL, Jones WS, Kraus WE, Lye RJ, Sanders JM, Allen JD, Regensteiner JG, Hiatt WR, Annex BH. Angiogenesis in skeletal muscle precede improvements in peak oxygen uptake in peripheral artery disease patients. Arterioscler Thromb Vasc Biol 2011;31:2742-2748.
21. Duscha BD, Schulze PC, Robbins JL, Forman DE. Implications of chronic heart failure on peripheral vasculature and skeletal muscle before and after exercise training. Heart Fail Rev 2008;13: 21-37.
22. Fernandes T, Magalh?es FC, Roque FR, Phillips MI, Oliveira EM. Exercise training prevents the microvascular rarefaction in hypertension balancing angiogenic and apoptotic factors: role of microRNAs-16, -21, and -126. Hypertension 2012;59: 513-520.
23. Hernandez N, Torres SH, Finol HJ, Vera O. Capillary changes in skeletal muscle of patients with essential hypertension. Anat Rec 1999;256: 425-432.
24. Courboulin A, Paulin R, Giguere NJ, Saksouk N, Perreault T, Meloche J, Paquet ER, Biardel S, Provencher S, Cote J, et al. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med 2011;208: 535-548.
25. Caruso P, Dempsie Y, Stevens H, McDonald RA, Long L, Lu R, White K, Mair K, McClure JD, Southwood M, et al. A role for miR-145 in pulmonary arterial hypertension. Circ Res 2012;111:290-300.
26. Pullamsetti SS, Doebele C, Fischer A, Savai R, Kojonazarov B, Dahal BK, Ghofrani HA, Weissmann N, Grimminger F, Bonauer A, et al. Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. Am J Respir Crit Care Med 2012;185:409-419.
27. Jakob P, Landmesser U. Role of microRNAs in stem/progenitor cells and cardiovascular repair. Cardiovasc Res 2012;93:614-622.
28. Nicoli S, Standley C, Walker P, Hurlstone A, Fogarty KE, Lawson ND. MicroRNA-mediated integration of haemodynamics and VEGF signalling during angiogenesis. Nature 2010;464:1196-1200.
29. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, Richardson JA, Bassel-Duby R, Olson EN. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008; 15:261-271.
30. Jakob P, Doerries C, Briand S, Mocharla P, Kränkel N, Besler C, Mueller M, Manes C, Templin C, Baltes C, et al. Loss of angiomiR-126 and 130a in angiogenic early outgrowth cells from patients with chronic heart failure: role for impaired in vivo neovascularization and cardiac repair capacity. Circulation 2012;126:2962-2975.
31. Mocharla P, Briand S, Giannotti G, Dorries C, Jakob P, Paneni F, Luscher T, Landmesser U. AngiomiR-126 expression and secretion from circulating CD341 and CD141 PBMCs: role for proangiogenic effects and alterations in type 2 diabetics. Blood 2013;121:226-236.
32. Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B, Hristov M, Köppel T, Jahantigh MN, Lutgens E, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009;2:ra81.
33. Brzoska E, Kowalewska M, Markowska-Zagrajek A, Kowalski K, Archacka K, Zimowska M, Grabowska I, Czerwińska AM, Czarnecka-Gora M, Stremińska W, et al. Sdf-1 (CXCL12) improves skeletal muscle regeneration via the mobilisation of Cxcr4 and CD34 expressing cells. Biol Cell 2012;104:722-737.
34. Espín R, Roca FJ, Candel S, Sepulcre MP, González-Rosa JM, Alcaraz-Perez F, Meseguer J, Cayuela ML, Mercader N, Mulero V. TNF receptors regulate vascular homeostasis in zebrafish through a caspase-8, caspase-2 and P53 apoptotic program that bypasses caspase-3. Dis Model Mech 2013;6:383-396.
35. Harris TA, Yamakuchi M, Kondo M, Oettgen P, Lowenstein CJ. Ets-1 and Ets-2 regulate the expression of microRNA-126 in endothelial cells. Arterioscler Thromb Vasc Biol 2010;30: 1990-1997.
36. Paulin R, Courboulin A, Meloche J, Mainguy V, Dumas de la Roque E, Saksouk N, CôtéJ, Provencher S, Sussman MA, Bonnet S. Signal transducers and activators of transcription-3/Pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension. Circulation 2011;123:1205-1215.
37. Kim E, Cook-Mills J, Morgan G, Sredni ST, Pachman LM. Increased expression of vascular cell adhesion molecule 1 in muscle biopsy samples from juvenile dermatomyositis patients with short duration of untreated disease is regulated by miR-126. Arthritis Rheum 2012; 64:3809-3817.
38. Mainguy V, Maltais F, Saey D, Gagnon P, Martel S, Simon M, Provencher S. Effects of a rehabilitation program on skeletal muscle function in idiopathic pulmonary arterial hypertension. J Cardiopulm Rehabil Prev 2010;30:319-323.
39. de Man FS, Handoko ML, Groepenhoff H, van 't Hul AJ, Abbink J, Koppers RJ, Grotjohan HP, Twisk JW, Bogaard HJ, Boonstra A, et al. Effects of exercise training in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2009;34:669-675.
40. Bader AG. MiR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet 2012;3:120.
41. Montgomery RL, Hullinger TG, Semus HM, Dickinson BA, Seto AG, Lynch JM, Stack C, Latimer PA, Olson EN, van Rooij E. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 2011;124:1537-1547.
42. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013;368:1685-1694.
43. Brock M, Samillan VJ, Trenkmann M, Schwarzwald C, Ulrich S, Gay RE, Gassmann M, Ostergaard L, Gay S, Speich R, et al. AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension. Eur Heart J [online ahead of print] 26 Mar 2012; DOI: 10.1093/eurheartj/ehs060.
44. Lamalice L, Houle F, Jourdan G, Huot J. Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38. Oncogene 2004; 23:434-445.
45. Lamalice L, Houle F, Huot J. Phosphorylation of Tyr1214 within VEGFR-2 triggers the recruitment of Nck and activation of Fyn leading to SAPK2/p38 activation and endothelial cell migration in response to VEGF. J Biol Chem 2006;281:34009-34020. [Published erratum appears in J Biol Chem 2007;282:10132.]